Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CVS$80.83+0.84(+1.05%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETGOOG$290.00+2.70(+0.94%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETINTC$56.96-1.32(-2.26%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,459.08-37.06(-2.48%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.50-8.20(-2.52%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.70+0.53(+1.15%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.78+0.92(+0.90%)Transaction in Own Shares8:00:53 AM ETIBM$256.00+1.68(+0.66%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$631.85+1.85(+0.29%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.00+1.81(+0.38%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$290.00+2.70(+0.94%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$354.71+5.20(+1.49%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$216.81+17.35(+8.70%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.00+1.68(+0.66%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETNVDA$197.01-3.28(-1.64%)Nvidia Stock Is Back at $200. What History Suggests Is the Floor.7:57:00 AM ETAAPL$354.71+5.20(+1.49%)Apple: Demand Is Not The Problem7:54:50 AM ETCOP$139.45+2.51(+1.83%)BRIEF-ConocoPhillips Says Qatar LNG Production Remained Constrained Through Q37:50:36 AM ETMCD$280.90+0.68(+0.24%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.23-4.47(-2.60%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.13+1.33(+0.24%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ETQCOM$153.40-19.79(-11.43%)Wall Street Breakfast Podcast: The VIX Plunges In Post-Election Rally7:47:00 AM ETKO$97.01+1.13(+1.18%)If You'd Invested $1,000 Alongside Warren Buffett in Coca-Cola, Here's How Much You'd Have Today7:47:00 AM ET

RNAC · NASDAQ

Cartesian Therapeutics, Inc.

$6.82 -0.04 (-0.58%)

Company overview

Cartesian Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302, which is in a Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212, which is in Phase III clinical trials for the treatment of chronic refractory gout, and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schönlein purpura. In addition, the company is developing gene therapies for the treatment of Pompe disease, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$206M
Employees
66
Headquarters
Watertown, MA
Website
selectabio.com
CEO
Carsten Brunn
Listed
June 22, 2016
P/E
-1.18
Dividend yield
0.00%

Company financials

Revenue
$1.8M
Gross profit
-$11M
Operating income
-$91.3M
EBITDA
-$67.3M
Net income
-$152M
EPS
-$5.79
Total assets
$288M
Total debt
$11.9M
Gross margin
-620.96%
Net margin
-8,550.65%
Earnings yield
-84.90%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

5.566.978.399.8011.21
RNAC 1D NASDAQ O6.64H7.16L6.54C6.86+0.45 (+7.02%)Vol49.45K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
RNACCartesian Therapeutics, Inc. Stock news Cartesian Therapeutics Q3 net loss narrows Reuters
RNACCartesian Therapeutics, Inc. Stock news BRIEF-Cartesian Therapeutics Inc Q3 Net Income USD -11.472 Million Reuters
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Announces New Employment Inducement Grant GlobeNewswire
RNACCartesian Therapeutics, Inc. Stock news Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical Comparison Defense World
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Announces New Employment Inducement GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Announces New Employment Inducement Grants GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Announces New Employment Inducement Grants GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
RNACCartesian Therapeutics, Inc. Stock news Kyverna Therapeutics Sinks 13%: Here's Why 24/7 Wall Street
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Announces New Employment Inducement Grants GlobeNewswire
RNACCartesian Therapeutics, Inc. Stock news Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ GlobeNewswire
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Announces New Employment Inducement Grants GlobeNewswire
RNACCartesian Therapeutics, Inc. Stock news Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates Zacks Investment Research
RNACCartesian Therapeutics, Inc. Press release Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire
RNACCartesian Therapeutics, Inc. Stock news Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet Seeking Alpha
See more
FAQ

Questions about Cartesian Therapeutics, Inc.

What does Cartesian Therapeutics, Inc. do?
Cartesian Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302, which is in a Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212, which is in Phase III clinical trials for the treatment of chronic refractory gout, and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schönlein purpura. In addition, the company is developing gene therapies for the treatment of Pompe disease, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases.
What is RNAC's market cap?
Cartesian Therapeutics, Inc. (RNAC) is a listed stock with a live quote. The latest market cap on this page is $206M.
Where is Cartesian Therapeutics, Inc. headquartered?
Cartesian Therapeutics, Inc. is headquartered in Watertown, MA.
How do I get RNAC news from the API?
Call GET /v1/news?tickers=RNAC. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does RNAC news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RNAC, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the RNAC price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs